   
   
_______________________________________________________________ _______________________ 
 1 1 
 2 
 3 
EFFICACY OF GABAPENTIN FOR  POST-COVID-19 OLFACTORY 4 
DYSFUNCTION 5 
 6 
 7 
Principal Investigator: 8 
Jay Piccirillo, MD, Department of  Otolaryngology-Head and Neck Surgery  9 
 10 
 11 
 12 
 13 
 14 
 15 
 16 
  17 
Version Date/Number:  18 
06/20/22,V11 19 
 20 
 21 
 22 
 23 
   
   
_______________________________________________________________ _______________________ 
 2TABLE OF CONTENTS 24 
 25 
A INTRODUCTION .................................................. ............................................................... .............. 4  26 
A1 STUDY ABSTRACT  .............................................................. ........................................................... 4  27 
A2 PRIMARY HYPOTHESIS  .............................................................. ..................................................... 4  28 
A3 PURPOSE OF THE STUDY PROTOCOL  .............................................................. ................................ 4  29 
B BACKGROUND .................................................... ............................................................... ............... 4  30 
B1 PRIOR LITERATURE AND STUDIES  .............................................................. .................................... 5  31 
B2 RATIONALE FOR THIS STUDY  .............................................................. ........................................... 6  32 
C STUDY OBJECTIVES .............................................. ............................................................... .......... 6  33 
C1 PRIMARY AIM .............................................................. ............................................................... ... 6 34 
C2 SECONDARY AIM .............................................................. ............................................................. 6  35 
C3 RATIONALE FOR THE SELECTION OF OUTCOME MEASURES  ........................................................... 6  36 
D INVESTIGATIONAL AGENT ......................................... ............................................................... .. 8 37 
D1 PRECLINICAL DATA .............................................................. ......................................................... 8  38 
D2 CLINICAL DATA TO DATE .............................................................. ................................................ 8  39 
D3 DOSE RATIONALE AND RISK/BENEFITS  .............................................................. ........................... 8  40 
E STUDY DESIGN .................................................. ............................................................... ................ 9  41 
E1 OVERVIEW OR DESIGN SUMMARY  .............................................................. ................................... 9  42 
E2 SUBJECT SELECTION AND WITHDRAWAL  .............................................................. ....................... 10  43 
2.a Inclusion Criteri a ............................................................................................................ ....... 10  44 
2.a Exclusion Cr iteria  ............................................................................................................ ....... 10  45 
2.b Ethical Consid erations ........................................................................................................ ... 10  46 
2.c Subject Recruitment Plans and Consent Process ................................................................... 11  47 
2.d Randomization Metho d and Bli nding ..................................................................................... 11  48 
2.e Risks and Benefits ............................................................................................................ ....... 11  49 
2.f Early Withdrawal  of Subjects................................................................................................... ... 12  50 
2.g When and How to W ithdraw Subjects ..................................................................................... 12  51 
2.h Data Collection and Follow-up  for Withdraw n Subjects ........................................................ 12  52 
E3 STUDY DRUG .............................................................. ............................................................... .. 12 53 
3.a Descrip tion ................................................................................................................... .......... 12  54 
3.b Treatment Regime n ............................................................................................................. .... 12  55 
3.c Method for Assigning Subject s to Treatment Groups ............................................................. 13  56 
3.d Preparation and Administra tion of Study Drug ...................................................................... 13  57 
3.e Subject Compliance Monitoring ............................................................................................. 13  58 
3.f Prior and Concom itant Therapy .................................................................................................  13 59 
3.g Packaging ..................................................................................................................... .......... 13  60 
3.h Blinding of Study Drug ........................................................................................................ ... 13  61 
3.i Receiving, Storage, Dispen sing and Return ................................................................................ 14  62 
F STUDY PROCEDURES .............................................. ............................................................... ...... 14  63 
F1 SCREENING FOR ELIGIBILITY  .............................................................. .............................................. 14  64 
F2 SCHEDULE OF MEASUREMENTS  .............................................................. ......................................... 14  65 
F3 SAFETY AND ADVERSE EVENTS  .............................................................. ......................................... 17  66 
3.a Safety and Complian ce Monito ring ........................................................................................ 17  67 
3.a Medical Mo nitori ng ............................................................................................................ .... 18  68 
i Investigat or only ............................................. ............................................................... ......................... 18  69 
3.b Definitions of Ad verse Events .................................................................................................  18 70 
   
   
_______________________________________________________________ _______________________ 
 3i Relationship .................................................. ............................................................... ........................... 19  71 
ii Severity ...................................................... ............................................................... .............................. 19  72 
iii Expectedness .................................................. ............................................................... ......................... 19  73 
3.c Data Collection Procedures  for Adverse Events .................................................................... 19  74 
3.d Reporting Pr ocedur es .......................................................................................................... ... 20  75 
3.e Adverse Event Repo rting Period............................................................................................. 20  76 
F4 STUDY OUTCOME MEASUREMENTS AND ASCERTAINMENT  ............................................................. 20 77 
G STATISTICAL PLAN .............................................. ............................................................... .......... 21  78 
G1 SAMPLE SIZE DETERMINATION AND POWER  .............................................................. .................. 21  79 
G2 INTERIM MONITORING AND EARLY STOPPING  .............................................................. ............... 21  80 
G3 STATISTICAL METHODS  .............................................................. ................................................. 21  81 
G4 MISSING OUTCOME DATA .............................................................. ............................................. 22  82 
G5 UNBLINDING PROCEDURES  .............................................................. ............................................ 22  83 
H DATA HANDLING AND RECORD KEEPING .............................. .............................................. 22  84 
H1 CONFIDENTIALITY AND SECURITY  .............................................................. ................................. 22  85 
H2 RECORDS RETENTION  .............................................................. .................................................... 23  86 
I STUDY ADMINISTRATION .......................................... ............................................................... . 23 87 
I1 SUBJECT STIPENDS OR PAYMENTS  .............................................................. ..................................... 23  88 
I2 STUDY TIMETABLE  .............................................................. ............................................................ 23  89 
J PUBLICATION PLAN .............................................. ............................................................... ........ 23  90 
K ATTACHMENTS ................................................... ............................................................... ............ 23  91 
K1 QUESTIONNAIRES OR SURVEYS  .............................................................. ...................................... 23  92 
L REFERENCES .................................................... ............................................................... ............... 24  93 
 94 
 95 
 96 
 97 
 98 
 99 
 100 
 101 
 102 
 103 
 104 
   
   
_______________________________________________________________ _______________________ 
 4 105 
A Introduction 106 
 107 
A1 Study Abstract 108 
COVID-19 has now infected over 33 million people in the United States and 109 
approximately 185 million worldwide.1,2 Of those, an estimated 85% have reported either 110 
a new clinical diagnosis or s ubjective onset of olfactory dysfu nction.3 While most 111 
patients will recover their se nse of smell within 7-14 days, ot hers may not return to their 112 
baseline function for months or at all.4 Viral infections that targ et the upper respiratory 113 
system, such as COVID-19, often leave patients with diminished olfaction. This new- 114 
onset anosmia, hyposmia, and parosmia is theorized to be caused  by damage to sensory 115 
neurons following viral insult. U nfortunately, there is no trea tment for post-COVID 116 
olfactory dysfunction. Most pati ents are recommended to perform  olfactory training with 117 
essential oils,5but the evidence base to support this recommendation is not fir m.6 Thus, 118 
there is a very big need for effective treatments for patients suffering from post-COVID 119 
olfactory dysfunction.  120 
 121 
One potential therapy is gabapent in. Used as an antiepileptic a nd now first-line 122 
medication for the treatment of  diabetic neuropathy, gabapentin  is known for reducing 123 
pain secondary to diabetic neur opathy and post-herpetic neuralg ia. Gabapentin works 124 
mainly on voltage-gated calcium c hannels (VGCC) with an ability  to cross the basement 125 
membrane, a trait important f or an antiepileptic. The α2δ2 subunit of  VGCCs, with 126 
increased expression in corticosp inal neurons, has been associa ted with loss of regrowth 127 
after spinal injuries. The α2δ2 blockage by gabapentin can allow increased nerve 128 
regeneration and return of function.7 Inhibition of the α2δ2 subunit on VGCCs may allow 129 
nerves to regenerate more rapi dly than physiologically normal. This study will evaluate 130 
the efficacy of gabapentin for olfactory dysfunction (anosmia, hyposmia, parosmia) in 131 
post-COVID-19 patients.  132 
A2 Primary Hypothesis 133 
We hypothesize that oral gabapentin will be more effective than  placebo for COVID-19- 134 
related olfactory dysfunc tion (OD) improvement. 135 
A3 Purpose of the Study Protocol 136 
This study will evaluate the e fficacy of gabapentin for olfacto ry dysfunction (anosmia, 137 
hyposmia, parosmia) in post-COVID-19 patients.  138 
 139 
B Background 140 
 141 
   
   
_______________________________________________________________ _______________________ 
 5B1 Prior Literature and Studies 142 
The SARS-CoV-2 virus, has infected an estimated 78 million in t he United States with 143 
~85% of patients reporting some form of olfactory dysfunction.1,3 More recent studies 144 
have shown an increased prevalence of olfactory change reported  in women over men 145 
and in Western countries when c ompared to Eastern countries.8,9 Moreover, the 146 
percentage of patients with pos t-COVID-19 olfactory dysfunction  is thought to be 147 
underreported as patients need to i ndividually report the sympt om to their physician for it 148 
to be recorded.9 149 
 150 
Evidence has emerged to explain the pathophysiology of COVID-19  and its mechanism 151 
of action on neurosensory pathways . Research suggests that COVI D-19 affects two genes 152 
commonly found in the human respiratory system, ACE2 and TMPRSS 2.10. ACE2, 153 
commonly associated with the renin -angiotensin-aldosterone syst em, has another role as 154 
a receptor protein on cell surf aces – a receptor proven vital f or SARS-CoV-2 to enter 155 
respiratory cells.11 Similarly, TMPRSS2 also plays a ro le in SARS-CoV-2 entry into cells 156 
and both genes are expressed i n neuronal support cells.7 ACE2 and TMPRSS2 are found 157 
only in support cells and not ne urons. The support cells, such as sustentacular cells, 158 
degenerate and are unable to sus tain neurons. This lack of neur onal stability is what 159 
likely causes the temporary neur osensory loss seen in post-COVI D-19 patients. However, 160 
evidence is now also s upporting the theory t hat COVID-19-relate d olfactory dysfunction 161 
may be due to direct damage to olfa ctory receptor neurons (ORNs ) as well, which would 162 
increase recovery time as neurons regenerate more slowly. Previ ous strains of human 163 
coronavirus have also been prove n to target ORNs causing olfact ory dysfunction but 164 
whether this direct damage to neur ons is related to ACE2 and TM PRSS2 has yet to be 165 
determined.10  166 
 167 
Patients who do recover their sens e of smell after infection te nd to notice improvement in 168 
just weeks, paralleling the rap id recovery rate of support cell s. Those with lingering 169 
olfactory dysfunction either ret urn to new normalcy in months i nstead of weeks or have 170 
yet to return to baseline. Some  patients report a return of sme ll followed shortly by new 171 
smell distortion. This observat ion of differing recovery rates supports the theory that 172 
SARS-CoV-2 also damages olfact ory receptor neurons directly lea ding to longer 173 
recovery times. Research has dem onstrated the po ssible utility in olfactory training, a 174 
therapy thought to encourage neur oplasticity via repeat exposur e to odors.6,12 However, 175 
the evidence to support this tr eatment is not universally accep ted and pharmacotherapy 176 
options for post-COVID-19 olfactor y dysfunction ar e still being  explored; one potential 177 
therapy is gabapentin.  178 
 179 
Gabapentin is an antiepileptic  medication now used as first-lin e therapy for diabetic 180 
neuropathy and herpetic neural gia. Gabapentin works by binding to VGCCs, which play 181 
an important role in neuronal synaptic transmission. More speci fically, gabapentin binds 182 
to α2δ isoforms which have been associ ated with neuropathic pain. The  postsynaptic α2δ1 183 
subunit promotes spinogenesis, t he development of neuronal dend ritic spines, while the 184 
α2δ2 works as a suppressor of axonal regeneration.13 Gabapentin functions as an inhibitor 185 
of the α 2δ2 subunit and therefore blocks  the suppression of axonal regen eration leading to 186 
increased neuronal regeneration and function. The medication is  effective in the treatment 187 
   
   
_______________________________________________________________ _______________________ 
 6of chronic pain and burning mouth s yndrome (BMS). The mode of a ction is thought to be 188 
primarily due to the fact that  gabapentin is highly lipophilic and can enter the central 189 
nervous system (CNS) and i ad in neuron regeneration.14 For these reasons, gabapentin is 190 
thought to have the potential t o improve post-COVID-19 olfactor y dysfunction caused by 191 
neuronal damage.  Our study will investigate the efficacy of ga bapentin to increase 192 
recovery of olfactory dysfuncti on secondary to post-COVID-19 in fection.  193 
 194 
B2 Rationale for this Study 195 
Olfactory dysfunction is a major symptom of SARS-CoV-2 affectin g up to 80% of 196 
infected individuals. While mos t have a return to normal olfact ory function in weeks, 197 
some may not see full improvement for months and a small percen tage may not recover 198 
function and suffer long-term  physical limitation and functiona l impairment. This 199 
placebo-controlled, double-blinded pilot RCT will evaluate the efficacy of oral 200 
gabapentin to improve chronic (> 3 months) olfactory dysfunction  secondary to COVID- 201 
19 infection. This study will provide data on the efficacy of g abapentin for the treatment 202 
of OD.  203 
 204 
C Study Objectives 205 
 206 
C1 Primary Aim 207 
To evaluate the efficacy of oral gabapentin on improvement of o lfactory dysfunction in 208 
patients with post-COVID-19 anosmia, hyposmia, or parosmia. Par ticipants will receive a 209 
maximum of 14weeks of either gaba pentin or placebo with the fir st four weeks serving as 210 
a titration phase and the last tw o weeks serving as a taper-dow n period. 211 
C2 Secondary Aim 212 
Describe the adverse effects of  gabapentin. All participants wi ll be monitored for adverse 213 
effects throughout the study.   214 
C3 Rationale for the Selection of Outcome Measures 215 
 216 
Primary Outcome:  217 
Clinical Global Impressi on of Improvement Scale  (CGI-I ). The response rate is 218 
defined as the number of partici pants self-report ing minimal ch ange or larger on 219 
the Clinical Global Impressi on of Improvement Scale  (CGI-I ) scale, divided by 220 
the number of participants i n each group. The CGI-Improvement is a self- 221 
reported scale of improvement ranging from 1  to 7 (1 is Very Much Improved, 7 222 
is Very Much Worsened) and will  be measured after completing 8 weeks of the 223 
fixed, highest-tolerable dose. Eac h rating is well defined to m aximize accuracy. 224 
Participants reporting 3 as Minimally Improved , 2 as Much Improved , or 1 as Very 225 
Much Improved  in the CGI-I will be deemed responders to treatment, and the 226 
number of responders to non-respon ders will be compared between  the two arms  - 227 
CGI-Severity (CGI-S) a nd CGI-Improvement (CGI-I).  228 
   
   
_______________________________________________________________ _______________________ 
 7 229 
 230 
Secondary Outcomes:  231 
1. CGI-Severity. The CGI-Severity  scale ranges from 1 to 7, where 1 is normal 232 
function and 7 is complete anosmia. This assessment will provid e subjective data 233 
on patients’ baseline olfactory f unction prior to beginning the  trial, after 8-week 234 
Fixed-Dose period, and 4 weeks af ter completion of Taper-Down p hase.   235 
2. CGI-Improvement . The CGI Improvement will also be administered 4 weeks 236 
after completion of Taper-Down phase  which same analysis as des cribed above.  237 
3. University of Pennsylvania Smell Identification Test  (UPSIT ).15 The UPSIT  is 238 
composed of 40 strips of micro encapsulated odorants, which are present on the 239 
bottom of each page, just below a four-alternative multiple-cho ice question. For a 240 
given item, the patient releas es an odor by scratching the micr oencapsulated pad 241 
with a pencil tip, smells the  pad, and indicates the odor quali ty from four 242 
alternatives. Even if no smell is  perceived, a response is requ ired (i.e., the test is 243 
forced-choice).  The subject's tot al correct score out of the 4 0 items is 244 
determined.16 245 
The total UPSIT score can ra nge from 0 to 40 and scores are int erpreted as the 246 
level of absolute smell func tion (i.e., normosmia, mild hyposmi a, moderate 247 
hyposmia, severe hyposmia, and anosmia), using the age- and sex -related 248 
normative classification system de scribed in the UPSIT manual ( Table 1) The 249 
minimal clinically important d ifference in UPSIT score is 4.  250 
 251 
4. Olfactory Dysfunction Outcomes Rating  (ODOR ). The ODOR  questionnaire is a 252 
28-item disease-specific health status survey to assess the phy sical problems, 253 
functional impairments, and emotional consequences secondary to  olfactory 254 
dysfunction. ODOR  was developed and validated by Dr . Jake Lee and colleagues 255 
in the Clinical Outcomes Resear ch Office at Washington Universi ty. 256 
5. NASAL-7 .  NASAL-7 is a simple diagnostic tool for ol factory dysfunction that is 257 
based on commonly found household items and can be used by adul ts who 258 
suspect olfactory dysfunction.  The NASAL-7 was developed by Dr. Piccirillo and 259 
colleagues in the Clinical Out comes Research Office. The NASAL-7 , contains 7 260 
household items with each item scored as 0 for ‘ Cannot Smell’ , 1 for ‘ Smells Less 261 
Strong/Different Than Normal ’, and 2 for ‘ Smells Normal’ , for a total possible 262 
score ranging from 0-14.  The fo llowing four categories of olfa ctory function 263 
were defined based on NASAL-7 score: anosmia  (score 0-4), severe dysfunction  264 
(score 5-7), mild dysfunction  (score 8-10), and normosmia  (score 11-14).  265 
6. Clinical Global Impression-Sever ity Scale for Parosmics (CGI-P ). The CGI-P  266 
Scale is a global rating of paro smia and the single global rati ng ranges from 1-5, 267 
where 1 is No Distortion , 2 is Mild Distortion , 3 is Moderate Distortion , 4 is 268 
Mostly Distorted , and 5 is Complete Distortion . The response on the CGI-P  will 269 
   
   
_______________________________________________________________ _______________________ 
 8provide information on the patient’ s perceived severity of the distortion of their 270 
smell.  271 
 272 
D Investigational Agent  273 
 274 
D1 Preclinical Data 275 
Gabapentin is an antiepileptic  medication now used as first-lin e therapy for diabetic 276 
neuropathy and herpetic neural gia. Gabapentin works by binding to voltage-gated 277 
calcium channels ( VGCCs), which play an important  role in neuronal synaptic 278 
transmission. More specifi cally, gabapentin binds to α2δ isoforms which have been 279 
associated with neuropathic pain.  280 
 281 
The α2δ2 subunit of  VGCCs, with increased expressi on in corticospinal neurons, has  282 
been associated with loss of reg rowth after spinal injuries. The postsynaptic α2δ1 subunit 283 
promotes spinogenesis, the develo pment of neuronal dendritic sp ines, while the α 2δ2 284 
works as a suppressor of axonal regeneration.13   The α2δ2 blockage by gabapentin can 285 
allow increased nerve rege neration and return of function.7 Inhibition of the α2δ2 subunit 286 
on VGCCs may allow nerves to rege nerate more rapidly than physi ologically normal.    287 
D2 Clinical Data to Date  288 
Gabapentin is an antiepileptic  medication now used as first-lin e therapy for diabetic 289 
neuropathy and herpetic neural gia. Gabapentin works by binding to voltage-gated 290 
calcium channels ( VGCCs), which play an important  role in neuronal synaptic 291 
transmission. More specifi cally, gabapentin binds to α2δ isoforms which have been 292 
associated with neuropathic pain.  293 
 294 
The medication has also proven eff ective in treated chronic pai n from Burning Mouth 295 
Syndrome (BMS) since gabapenti n is highly lipophilic and can en ter the central nervous 296 
system (CNS).14 For these reasons, gabapentin i s thought to have the potential  to improve 297 
post-COVID-19 olfactory dysfuncti on caused by neuronal damage.  Gabapentin can 298 
penetrate the blood-br ain barrier and enter the CNS where it ca n aid in neuron 299 
regeneration.  300 
D3 Dose Rationale and Risk/Benefits  301 
Gabapentin dosing for this st udy mirrors dosing for the prior s tudy “Relief of Idiopathic 302 
Subjective Tinnitus” (IRB #02-0717) 303 
Following randomization, participants in the gabapentin arm wil l take gradually titrated 304 
dosages in order to achieve a  dose of 3600mg/d or highest toler able dose. The titration 305 
schedule will span a maximum 4 weeks to reach 3600mg/d.  306 
 Week 1, 900 mg/d 307 
 Week 2, 1800 mg/d 308 
 Week 3, 2700 mg/d 309 
 Week 4, 3600 mg/d 310 
 311 
   
   
_______________________________________________________________ _______________________ 
 9Gabapentin (300 mg per capsule) and placebo will be supplied to  patients in 312 
identical opaque capsules in bli nded fashion. The medications w ill be distributed in 4 313 
separate vials representing eac h of the four weeks of the Titra tion Period.  All 314 
participants will be provided an e qual number of capsules and i nstructed to follow a TID 315 
(i.e., 3 times per day) dosing sch edule.  All participants’ dos ages will be titrated to a 316 
maximum dose of 3600 mg/d, regardle ss of any possible beneficia l effect achieved at 317 
lower dosages. If intolerable a dverse reactions occur, the dosa ge will be decreased to 318 
previous tolerable dose (e.g. i f 2700mg/d is intolerable, dosag e will be decreased to 1800 319 
mg/d). If, during the first w eek, 900 mg/d is intolerable, dosi ng will be decreased by 300 320 
mg/d per day until tolerable (i.e., 600 mg/d, 300mg/d) or until  they are no longer taking 321 
the medication. The dose estab lished during the Titration Perio d will be maintained 322 
throughout the Fixed-Dose period.  Participants receiving the m atching placebo capsules 323 
will be provided similar instru ctions for titration and de-esca lation, should side effects 324 
develop.   325 
 326 
The potential benefit to the part icipant is improvement of thei r olfactory dysfunction 327 
using this therapy. The potential  benefit to the society is the  use of the pilot study results 328 
to initiate a larger trial to further eva luate the efficacy of gabapentin in the treatment of 329 
post-COVID-19 olfactory dysfunction. 330 
 331 
The potential risk to participan ts during the study is an adver se event associated with the 332 
medication use. Abrupt cessation of  gabapentin may alter the se izure threshold; for this 333 
reason, participants will be provided with a taper schedule spe cific to the gabapentin dose 334 
at time of completion of the Fix ed Dose period. Gabapentin has a slight risk of 335 
dependence in patients with prev ious history of alcohol, cocain e, or opioid abuse so these 336 
individuals will be e xcluded from the study. 17 337 
 338 
E Study Design  339 
 340 
E1 Overview or Design Summary 341 
This study will be a double-blinded, placebo-controlled, random ized pilot clinical trial to 342 
evaluate the efficacy of gabape ntin to improve post-COVID-19 ol factory dysfunction. 343 
This study will also describe adverse effects related to oral g abapentin use.  344 
 345 
This study will be conducted via  virtual research guidelines an d procedures. We will not 346 
require in-person patient partic ipation or evaluation. Followin g initial evaluation to 347 
ensure potential participants m eet all inclusion criteria and n one of the exclusion criteria, 348 
the research study will be expl ained in full via Zoom call, pho ne call if necessary. 349 
Participants will then be randomized in a 1:1 allocation via pe rmuted-block sequencing 350 
into the oral gabapentin group or the placebo group. All assess ments will be conducted 351 
through a HIPAA-compliant online su rvey form. Baseline assessme nts will help us 352 
determine subjective and objectiv e rates of olfactory dysfuncti on. Assessments will be 353 
conducted again after the 8-w eek Fixed-Dose period and 4 weeks after comple ting taper.  354 
   
   
_______________________________________________________________ _______________________ 
 10The primary objective of this study is to assess the efficacy o f oral gabapentin in 355 
improving olfactory dysfunc tion secondary to COVID-19. 356 
E2 Subject Selection and Withdrawal  357 
 358 
2.a Inclusion Criteria  359 
Participants will be recruited ba sed on the following inclusion  criteria:   360 
- Men and women between the ages of 18 and 65 years  361 
- Residing within the states  of Missouri or Illinois  362 
- Clinically diagnosed or subjectiv e olfactory dysfunction (anosm ia, hyposmia, 363 
or parosmia) of at least 3 m onths duration  associated with COV ID-19 364 
infection  365 
- initial UPSIT score consistent  with diminished olfactory functi on (score > 6 366 
and  ≤ 33 in men and score > 6 and ≤ 34 in women). 367 
- Willing to respond daily to study surveys, preferably through s martphone with 368 
unlimited texting plan. 369 
- In possession of all 7 househol d items associated with NASAL-7 : soap, burnt 370 
candle, peanut butter, her b, garlic, lemon, and coffee 371 
 372 
2.a Exclusion Criteria  373 
Individuals will not b e allowed to participate in this study if  they meet one or more of the 374 
following exclusion criteria:  375 
- Clinically diagnosed olfactor y dysfunction secondary to non-COV ID-19 viral 376 
infection, genetic abnormalities  or congenital dysfunction, tra uma, nasal 377 
polyps, neurodegenerative disorders 378 
- Current use of: azelastine, bromperidol, orophenadrine, oxomema zine, 379 
kratom, paraldehyde, or thalidomide 380 
- History of addiction to alc ohol, cocaine, or opioids 381 
- Impaired renal function, myast henia gravis, or myoclonus  382 
- Severe allergy to peanuts 383 
- Pregnancy or attempting pregnanc y during study participation 384 
- Inability to participate in virt ual trial due to lack of access  to the; inability to 385 
comprehend or use English language 386 
- Availability less than 18 week s from time of enrollment 387 
- Residency in states other th an Missouri or Illinois. 388 
2.b Ethical Considerations  389 
This study relies on participati on of human subjects. Informed consent will be 390 
obtained from each participant to e nsure their safety, minimize  risk, and ensure full 391 
confidentiality. All assessment s will be conducted virtually vi a HIPAA-compliant online 392 
surveys at baseline and then t hroughout the study course. Selec tion of participants for the 393 
study will consider the variabil ity in response to COVID-19 as well as response to 394 
gabapentin by ensuring the tw o groups are matched 1:1 by permut ed block 395 
randomization. Gabapentin has a sl ight risk of dependence in in dividuals with previous 396 
   
   
_______________________________________________________________ _______________________ 
 11history of alcohol, cocaine, or opioi d abuse so these patients will be excluded from the 397 
study.17The study team will be available at all times for participants during the full course 398 
of the trial.  399 
2.c Subject Recruitment Plans and Consent Process 400 
Recruitment will be done at the  Washington University Departmen t of Otolaryngology- 401 
Head and Neck Surgery outpatient clinics. Advertisements will a lso be sent to all 402 
members of the St. Louis ENT Club, and otolaryngologists whose practices are within 403 
150 miles of Washington Universit y Medical Center (WUMC). Direc t recruitment of 404 
potential participants will als o be achieved through use of the  Washington University 405 
Volunteers for Health Research P articipant Registry, and the Ot olaryngology Research 406 
Participant Registry. This recr uitment strategy has been succes sful for two current trials 407 
of treatment for COVID-asso ciated anosmia VOLT (IRB ID# 2020110 46) and SCENT2 408 
(IRB ID# 202101190). We may also attemp t to recruit potential p articipants from past 409 
studies in our lab, such as t he CODS trial (IRB ID# 202004146).  Additionally, due to the 410 
focus on virtual research at th is time, we may also use website  postings and work with 411 
anosmia support groups such as AbScent and FifthSense to share the trial. 412 
2.d Randomization Method and Blinding 413 
Participants who remain eligib le at the end of the screening pe riod will be randomized in 414 
a double-blind fashion, according to a computer-generated rando m code, to receive either 415 
placebo or gabapentin. Dr. Kallogjeri will provide the randomiz ation table to the BJH 416 
Research Pharmacist, who will prepare both gabapentin and place bo for the entire study.  417 
The research assistants will collect the gabapentin and placebo  in a blinded fashion from 418 
the research pharmacist for dist ribution to the pa rticipants vi a FedEx.   419 
2.e Risks and Benefits 420 
The potential benefit to the part icipant is improvement of thei r olfactory dysfunction 421 
using this therapy. The potential  benefit to the society is the  use of the pilot study results 422 
to initiate a larger trial to further eva luate the efficacy of gabapentin in the treatment of 423 
post-COVID-19 olfactory dysfunction.  424 
 425 
The potential risk to participan ts during the study is an adver se event associated with the 426 
medication use. Abrupt cessation of  gabapentin may alter the se izure threshold; for this 427 
reason, participants will be provided with a taper schedule spe cific to the gabapentin dose 428 
at time of cessation. Gabapenti n has a slight risk of dependenc e in individuals with 429 
previous history of alcohol, coc aine, or opioid abuse so these individuals will be excluded 430 
from the study. 17 431 
 432 
The consent process informs a volunteer about the study, indica tes that participation is 433 
voluntary, and that he/she has the right to stop at any time. R isks are listed in the 434 
informed consent form and descri bed orally during the consent p rocess.  435 
 436 
   
   
_______________________________________________________________ _______________________ 
 122.f Early Withdrawal of Subjects  437 
If a subject decides to withdraw from all components of the res earch study, the 438 
investigator will discontinue all  of the current and scheduled research activities in the 439 
study. Participants taking an int ervention medication at the ti me of withdrawal will be 440 
provided with a taper-down sche dule based on maximum interventi on dose achieved.  441 
 442 
2.g When and How to Withdraw Subjects  443 
A participant can withdraw cons ent for the study at any time. P articipants will be allowed 444 
to end participation in the st udy at any point should they desi re. If a participant must be 445 
withdrawn due to a drug-related s erious adverse event, then bli nd will be broken and, if 446 
on gabapentin, drug withdrawal will  be tapered or completely st opped based on the 447 
clinical judgement of the PI. All participants will have an exi t interview to ascertain any 448 
adverse effects and discuss the reason for endi ng participation . The study team will 449 
follow them for safety reas ons up to 30 days after stopping use  of the study drug.  450 
 451 
2.h Data Collection and Follow-up for Withdrawn Subjects  452 
If a participant has ended part icipation, the onl y data that wi ll be collected are the data 453 
from the exit interview and the  data collected prior to withdra wal.  There will not be any 454 
other follow-up or data collect ed from these subjects.   455 
 456 
Data collected up to this point wil l not be used in the analysi s, and further data  will not be 457 
collected from these participants.  458 
 459 
E3 Study Drug  460 
 461 
3.a Description  462 
Gabapentin is an antiepileptic  medication now used as first-lin e therapy for diabetic 463 
neuropathy and herpetic neural gia. Gabapentin works by binding to voltage-gated 464 
calcium channels ( VGCCs), which play an important  role in neuronal synaptic 465 
transmission. More specifi cally, gabapentin binds to α2δ isoforms which have been 466 
associated with neuropathic pain.  467 
3.b Treatment Regimen  468 
During the titration period of max imum 4 weeks, participants ra ndomized to 469 
the gabapentin arm will take gradually titrated dosages of gaba pentin as follows:  470 
 Week 1, 900 mg/d (300 mg TID) 471 
 Week 2, 1800 mg/d (600 mg TID) 472 
 Week 3, 2700 mg/d (900 mg TID) 473 
 Week 4, 3600 mg/d (1200 mg TID) 474 
 475 
If intolerable effects occur, dosage will be decreased by 1 dos e (300 mg) step (e.g. if 476 
2700 mg/d is intolerable, dosag e will be decreased to 2400 mg/d ).  Further de-escalation 477 
   
   
_______________________________________________________________ _______________________ 
 13will be determined by PI clinical  judgement to prior tolerable dose. The highest tolerable 478 
dose established during the Titra tion Period will be maintained  throughout the 8-week 479 
Fixed-Dose period.   480 
3.c Method for Assigning Subjects to Treatment Groups  481 
The participants will be divid ed using permuted block randomiza tion in a 1:1 allocation 482 
between two arms: the oral gaba pentin group and the oral lactos e placebo group with 20 483 
persons in each group. 484 
3.d Preparation and Administration of Study Drug  485 
Gabapentin (300 mg per capsule) and placebo will be supplied to  patients in identical 486 
opaque capsules in blinded fashion.  The medications will be di stributed in 4 separate 487 
vials representing each of the f our weeks of the Titration Peri od and distributed in 8 488 
separate vials prior to t he Fixed-Dose period.  489 
3.e Subject Compliance Monitoring  490 
There will be check-ins with the  study participants every two w eeks conducted virtually 491 
through the participant’s prefe rred communicatio n method (i.e. phone call or video call) 492 
to answer questions and ensure pa rticipants are adhering to med ication schedule. Subjects 493 
will be asked to keep a paper cal endar for daily notes of pill count, side/adverse effects, 494 
and study barriers. The paper calendar will be mailed back to t he RA after study 495 
completion. 496 
3.f Prior and Concomitant Therapy  497 
Patients receiving concomitant t herapy specifically for the tre atment of olfactory 498 
dysfunction will not be eligible for the tri al unless they are able to stop taking those 499 
therapies during the conduct of  the study. Participants who hav e tried previous therapies 500 
for their olfactory dysfunction, including over-the-counter tre atments such as vitamin A 501 
or omega-3 fatty acids will be eligible for the trial. Informat ion will be gathered on their 502 
use of prior or current therapi es, and if needed, a sensitivity  or subgroup analysis may be 503 
considered.  504 
 505 
3.g Packaging  506 
The Research Pharmacist will deliver the gabapentin and placebo  in a blinded fashion to 507 
the research assistant for dist ribution to the participants via  FedEx.   508 
3.h Blinding of Study Drug  509 
Participants will be divided into two groups; one group will be  given oral gabapentin 510 
while the other group will be given oral placebo. The research pharmacist will receive the 511 
randomization assignment code fro m the biostatistician. The RA will pick up the study 512 
drug in blinded fashion from res earch pharmacist and distribute  it to the participant via 513 
FedEx delivery. In this way, only the Research Pharmacist will know participant 514 
assignment.  Adequate taper of ga bapentin will be provided for those on gabapentin while 515 
the placebo group will receive addi tional placebo for taper in order to maintain the blind.  516 
   
   
_______________________________________________________________ _______________________ 
 143.i Receiving, Storage, Dispensing and Return  517 
The services of the Investigati onal Pharmacy at Barnes-Jewish H ospital will be used for 518 
this trial.  The product used in this trial will be managed by the pharmacist according to 519 
the pharmacy SOP. 520 
F Study Procedures  521 
 522 
F1 Screening for Eligibility 523 
Individuals who reach out with interest in the study after seei ng the approved study flyer 524 
or who have contacted RA for par ticipation in similar studies f or which recruitment has 525 
ended will asked to complete an online screening questionnaire (survey titled: 526 
“ScreeningSurvey”) to ensure he  or she meets all the inclusion criteria and does not meet 527 
any exclusion criteria. Follo wing eligibility confirmation, the  RA will collect information 528 
required to mail screening smell identification test (UPSIT).  Once received, the 529 
participant will complete the UPSIT and provide their response virtually through the 530 
REDCap survey.  Once eligibil ity is confirmed based on UPSIT sc ore, participants will 531 
be provided through REDCap an online consent form to review and  complete. The RA 532 
will offer each participant the  option to review the consent fo rm independently or with 533 
the RA via zoom or phone call (zoom as the preferred option). O nce the participant 534 
electronically signs the consent form, the RA will review it an d sign.  The REDCap 535 
software will automatically ema il the particip ant a copy of the ir completed form. 536 
F2 Schedule of Measurements 537 
Following the recruitment period and successful enrollment, bas eline survey completion 538 
(survey titled Week0BaselineS urvey) and randomization of partic ipants will occur. The 539 
timeline for measurements can be seen below.  540 
 541 
Gabapentin Study Flow Chart  542 
 543 
 544 
 545 
 546 
 547 
 548 

   
   
_______________________________________________________________ _______________________ 
 15 549 
 550 
 551 
 552 
 553 
a. Federal guidelines require timely repor ting (within 15 calendar days) of an 554 
unanticipated or life-threat ening event or death occurring within 30 days of 555 
active study participation. 556 
 557 
 558 
Titration Period: max imum duration 4 weeks 559 
 560 
Placebo .  In this study, we plan to use  an inert placebo and not an ac tive drug 561 
or non-active drug with side effect s similar to gabapentin.  Pa rticipants randomized to the 562 
Placebo arm will participate in a  4-week Titration Period. Plac ebo will be supplied to 563 
patients in opaque capsules i n blinded fashion.  The medication s will be distributed in 4 564 
separate vials representing eac h of the four weeks of the Titra tion Period.  If intolerable 565 
adverse reactions occur, the dos age will be decreased to prior tolerable dose. 566 
Gabapentin .  Participants randomized to the gabapentin arm will take 567 
gradually titrated dosages of  gabapentin as follows:  568 
 569 
 Week 1, 900 mg/d (300 mg TID) 570 
 Week 2, 1800 mg/d (600 mg TID) 571 
 Week 3, 2700 mg/d (900 mg TID) 572 
 Week 4, 3600 mg/d (1200 mg TID) 573 
 574 
Gabapentin (300 mg per capsule) will be supplied to participant s in opaque 575 
capsules in blinded fashion identical to the supply of Placebo.   The medications will be 576 
distributed in 4 separate vials representing each of the four w eeks of the Titration Period. 577 
All participants’ dosages will  be titrated to a maximum dose of  3600 mg/d, regardless of 578 
any effect achieved at lower dosag es. If intolerable effects oc cur, dosage will be 579 
decreased by 1 dose (300 mg) s tep (e. g. if 2700 mg/d is intole rable, dosage will be 580 
decreased to 2400 mg/d).  Further  de-escalation will be determi ned by PI clinical 581 
judgement to prior tolerable dose . Participants with intolerabl e effects may have a lower 582 
maximum dose than 3600mg/d and ma y complete the Titration Perio d in less than 4 583 
weeks. The dose established duri ng the Titrati on Period will be  maintained throughout 584 
the Fixed-Dose period.     585 
   
   
_______________________________________________________________ _______________________ 
 16
 586 
Gabapentin (300 mg pill) Titration Schedule 587 
 588 
If at any point during the Titra tion Period, the participant wi shes to discontinue 589 
the medication for any reason, they will be instructed to follo w the taper down schedule 590 
(see below) in order to safely s top the medication.  The partic ipant will be informed that 591 
any abrupt stoppage of gabapentin c ould cause serious adverse e ffects. 592 
Participants will be contact ed by telephone or video call by th e Research Assistant 593 
(RA) at the end of Titration pe riod.  The purpose of this call will be to query the 594 
participants about adverse effect s.  Participants will be provi ded with a paper calendar 595 
and asked to maintain diaries of  olfactory and taste symptoms a nd adverse effects 596 
possibly related to the intervention. 597 
Participants will not complete any forms at the completion of T itration period. 598 
Instead, they will pr oceed directly to Fi xed-Dose Period. 599 
 600 
Fixed-Dose Period: duration 8 weeks  601 
During the Fixed-Dose period, participant’s dose will remain at  their maximum tolerated 602 
dosage established during the  Titration phase.  The study drug will be distributed in eight 603 
separate vials representing the e ight weeks of the Fixed-Dose p eriod.  The RA will 604 
contact the participants at th e end of Week 4 to administer the  blind assessment using 605 
REDCap (survey titled: “Blind A ssessment”). Participants will c omplete the following 606 
forms after completing the Fixed -Dose Period (survey titled: “F ixedDoseSurvey”): 607 
 608 
1.) Clinical Global Impression of Severity Scale  (CGI-S ). 609 
2.) Clinical Global Impression of  Improvement Scale (CGI-I)  610 
3.) University of Pennsylvani a Smell Identification Test  (UPSIT ) 611 
4.) Olfactory Dysfunction Outcomes Rating  (ODOR ) 612 
5.) NASAL-7  613 
6.) Clinical Global Impression-Severity Scale for Parosmics (CGI-P)  614 
7.) Adverse Event assessment 615 
8.) Compliance 616 
 617 
Adverse events . Any unintentional or unfavorable c linical sign or symptom, an y new 618 
illness or disease or the deterioration of existing disease or illness, or any clinically 619 
significant deterioration in any l aboratory assessments or clin ical tests while participating 620 
in this study will be captured. T he study coordinator will cont act participants virtually to 621 
answer questions and assess advers e effects afte r Titration per iod, Fixed-Dose period, 622 
and 4 weeks after Taper.  623 
 624 
   
   
_______________________________________________________________ _______________________ 
 17Taper Down: maximum duration 2 weeks    625 
Upon completion of the Fixed-Dos e period, all participants in t he study will be 626 
titrated off study drug through a tap er down period of maximum 2 weeks. Taper schedule 627 
will directly relate to maxim um gabapentin dose achieved during  trial and is described in 628 
the Table below. The study dr ug will be distributed in 2 separa te vials representing each 629 
of the two weeks of the Tape r-Down Period. It should be noted, participants randomized 630 
to placebo will also receive sufficient capsules to complete a taper down. In this way, the 631 
blind will be maintained.  632 
 633 
Gabapentin Taper Down Schedule 634 
 635 
End of Study Intervention: Exit Interview/ Data Collection: 4 w eeks after 636 
completing Taper Down    637 
The RA will contact the particip ants to query participants abou t compliance 638 
with taper-down schedule and mai ntenance of diaries. Participan ts will complete the 639 
following forms (survey tit led: “FinalSurvey”):  640 
1. Clinical Global Impression of Severity Scale  (CGI-S ). 641 
2. Clinical Global Impression of  Improvement Scale (CGI-I)  642 
3. University of Pennsylvani a Smell Identification Test  (UPSIT ) 643 
4. Olfactory Dysfunction Outcomes Rating  (ODOR ) 644 
5. NASAL-7  645 
6. Clinical Global Impression-Severity Scale for Parosmics (CGI-P)  646 
 647 
F3 Safety and Adverse Events  648 
 649 
3.a Safety and Compliance Monitoring 650 
The specific monitoring pla n for this study is based on the pot ential risk of participation 651 
and size and complexity of the  planned investigation.  Based on  these considerations, this 652 
study will have a monitoring comm ittee comprised of Dr. Picciri llo, Ms. Kukuljan, and 653 
Dr. Kallogjeri, the study bios tatistician. All re ports of a Ser ious Adverse Event (SAE) or 654 
   
   
_______________________________________________________________ _______________________ 
 18an Unexpected Adverse Event (UAE) will be investigated by the m onitoring team and 655 
reported to Washington Universi ty HRPO according to the reporti ng requirements.  656 
 657 
Participants who experience serious  adverse effects with gabape ntin therapy will be 658 
removed from the study. Participa nts with serious adverse effec ts will be instructed to 659 
call 911, seek immediate medical  care and discontinue all furth er gabapentin treatment. If 660 
tolerated, all participants w ill complete the Titration period (≤ 4 weeks), Fixed-Dose 661 
period (8 weeks), and Taper-Down period (2 weeks) for maximum 1 4 weeks of active 662 
participation.  In addi tion, there will be a  4-week, post-Taper  completion follow-up for 663 
maximum total of 18-week trial duration. 664 
3.a Medical Monitoring  665 
 666 
i Investigator only 667 
The PI and the study team will be monitoring patients for any s afety concerns, such as 668 
SAE or UAE, in real time for t he duration of the 18-week study.  In addition, participants 669 
will be specifically asked about  any adverse events after the F ixed-Dose period via 670 
REDCap. Participants will be able to get in touch with a member  of the study team 24/7 671 
via phone or pager for the durat ion of the 18-week clinical tri al. The study biostatistician 672 
will hold the randomization code s and remain blinded to the int ervention assignment. In 673 
the event of an SAE or UAE in whi ch the blind needs to be broke n, the Research 674 
Pharmacist will be contacted by th e PI or a member of the study  team.  The participant 675 
will receive appropriate care and will be removed from the tria l. A description of the 676 
event will be included in the rep ort of adverse events for the clinical study. 677 
 678 
3.b Definitions of Adverse Events 679 
Adverse event (AE) means any untoward medical occurrence associ ated with the use of a 680 
drug in humans, whether or not cons idered drug related (21 CFR 312.32(a)). 681 
 682 
An adverse event (also referred t o as an adverse experience) ca n be any unfavorable and 683 
unintended sign (e.g., an abnorma l laboratory finding), symptom , or disease temporarily 684 
associated with the use of a  drug, without any judgment about c ausality or relationship to 685 
the drug. 686 
 687 
An adverse event can arise fro m any use of the drug (e.g., off- label use, use in 688 
combination with another drug) and from any route of administra tion, formulation, or 689 
dose, including an overdose. 690 
 691 
Serious adverse events (SAEs) are  special cases of an adverse e vent where adverse 692 
outcomes are severe. SAEs include the following events: 693 
 694 
• Death of any of the participants a ssociated with a clinical tri al. 695 
• An event which can lead to life- threatening complications or pu t the life of 696 
participants at risk as a resu lt of participation in a clinical  trial. 697 
   
   
_______________________________________________________________ _______________________ 
 19• Events that result in such a c ondition where the participants m ay require 698 
immediate hospitalization or inc rease the duration of hospitali zation. 699 
• Any events that lead to a perma nent or temporary physical disab ility in the body 700 
of the participants. Any sort of i ncapacity is also regarded as  SAE. 701 
• Any events that lead to any type of congenital abnormalities. I t also includes any 702 
cases of birth defects resulting f rom the clinical trials. 703 
• Any events where an investigator  or team of investigators finds  feel that it can 704 
lead to significant hazards. 705 
 706 
Classification of Events 707 
 708 
i Relationship 709 
An AE or SAE may or may not be causally related to the study in tervention. A causal 710 
relationship means that the int ervention caused (or is reasonab ly likely to have caused) 711 
the AE. This usually implies a re lationship in time between the  intervention and the AE 712 
(e.g., the AE occurred shortly after the participant received t he intervention).  For all 713 
AEs, it is the responsibility of t he Principal Investigator who  examines and evaluates the 714 
patient to determine the relatedness of the event to the study intervention. 715 
 716 
ii Severity 717 
Severity refers to the intensit y of a specific event and is a m atter of individual clinical 718 
judgment.  719 
• Grade 1:  Asymptomatic or mild s ymptoms; clinical or diagnostic  observations 720 
only; no intervention indicated 721 
• Grade 2: Moderate; minimal, lo cal or noninvasive intervention i ndicated; limiting 722 
age-appropriate instrumental activities of da ily living (ADL) 723 
• Grade 3: Severe; or medically s ignificant but not immediately l ife- threatening; 724 
hospitalization or prolongation of  hospitalization indicated; d isabling; limiting 725 
self-care ADL 726 
• Grade 4: Life-threatening; ur gent intervention indicated. 727 
• Grade 5: Death related to an AE 728 
 729 
iii Expectedness 730 
 731 
An adverse event or suspected adv erse reaction is considered "u nexpected" if it is not 732 
consistent with the risk infor mation described in this protocol  or on the informed consent 733 
or is not listed at the specific ity or severity that has been o bserved; or, if an investigator 734 
brochure is not required or ava ilable, is not consistent with t he risk information described 735 
in the general investigational plan or elsewhere in the current  application, as amended. 736 
3.c Data Collection Procedures for Adverse Events 737 
All adverse events and suspected  adverse reactions are collecte d from ‘source 738 
documentation’ and the research coordinator will abstract the e vents.  Documentation can 739 
   
   
_______________________________________________________________ _______________________ 
 20be within Washington University E PIC medical records, but at ti mes the research 740 
coordinator will also need to have the subject or family send o utside source 741 
documentation. 742 
 743 
3.d Reporting Procedures 744 
The Principal Investigator (P I) will be responsib le for ensurin g participants’ safety on a 745 
daily basis and for reporting Ser ious Adverse Events and Unanti cipated Problems to the 746 
Institutional Review Boa rd (IRB) as required. 747 
 748 
All SAEs will be reported immedia tely to the Principal Investig ator upon identification. 749 
3.e Adverse Event Reporting Period 750 
 751 
All AEs and unanticipated problems will be reported to the IRB in a prompt and timely 752 
manner to protect other subjects from avoidable harm. The appro priate time frame for 753 
satisfying the requirement for pr ompt reporting will vary depen ding on the specific nature 754 
of the unanticipated problem.  F or this study, unanticipated pr oblems that are serious 755 
adverse events will be reported to the IRB within 1 week of the  investigator becoming 756 
aware of the event.  Any other una nticipated problem will be re ported to the IRB within 2 757 
weeks of the investigator becoming aware of the problem.   758 
 759 
Determining the appropriate time  frame for re porting a particul ar unanticipated problem 760 
requires careful judgment by the  Research Coordinator and the P rincipal Investigator 761 
knowledgeable about human subject pr otections.  The primary con sideration in making 762 
these judgments is the need to t ake timely action to prevent av oidable harms to other 763 
subjects.   764 
 765 
F4 Study Outcome Measurements and Ascertainment 766 
Participants will complete an assessment of blind after complet ion of 4 weeks of 767 
the 8-week Fixed-Dose period usin g REDCap (survey titled: “Blin d Assessment”) 768 
 769 
Participants will also complete the following forms using REDCa p (survey titled 770 
“FixedDoseSurvey”) after comple ting the 8-week Fixed-Dose Perio d: 771 
 772 
1.) Clinical Global Impression of Severity Scale  (CGI-S ). 773 
2.) Clinical Global Impression of  Improvement Scale (CGI-I)  774 
3.) University of Pennsylvani a Smell Identification Test  (UPSIT ) 775 
4.) Olfactory Dysfunction Outcomes Rating  (ODOR ) 776 
5.) NASAL-7  777 
6.) Clinical Global Impression-Severity Scale for Parosmics (CGI-P)  778 
7.) Adverse Event assessment 779 
8.) Compliance 780 
 781 
   
   
_______________________________________________________________ _______________________ 
 21Participants will also complete the following forms using REDCa p (survey titled 782 
FinalSurvey) 4 weeks after co mpleting the Taper Period. 783 
1) Clinical Global Impression of Severity Scale  (CGI-S ). 784 
2) Clinical Global Impression of  Improvement Scale (CGI-I)  785 
3) University of Pennsylvani a Smell Identification Test  (UPSIT ) 786 
4) Olfactory Dysfunction Outcomes Rating  (ODOR ) 787 
5) NASAL-7  788 
6) Clinical Global Impression-Severity Scale for Parosmics (CGI-P)  789 
 790 
 791 
G Statistical Plan  792 
 793 
G1  Sample Size Determination and Power 794 
To date there have been no studies investigating efficacy of ga bapentin in COVID-19 795 
related olfactory dysfunction. Due  to the lack of preliminary d ata and effect size, 796 
estimates of the sample size for this study will be determined based on feasibility. For 797 
this pilot study, we plan to enro ll 60 subjects. The sample siz e of 60 subjects is feasible 798 
given the incidence of COVID-19 cases in Missouri and consideri ng a conservative 799 
estimate of a 10% rate of perman ent olfactory dysfunction among  those (~50%) who 800 
experience olfactory dysfunction a s one of the presenting sympt oms. Using a 33% drop 801 
out rate, we estimate that the  sample size of 60 subjects rando mized in a balanced way 802 
between the two treatment groups  will provide us with 40 evalua ble cases. A previous 803 
study exploring a different treat ment for COVID-19 related anos mia in our lab showed 804 
that 30% of the participants r andomized to placebo reported imp rovement at the end of 805 
the trial as compared to baseli ne.  We aim to observe a 25% dif ference in the response 806 
rate between gabapentin and placebo groups. Assuming that this will be the response rate 807 
in the placebo group of our trial, the sample size of 20 subjec ts per group will provide us 808 
with a 95% Confidence Interval  -5% to 55% around the desired pr oportion difference of 809 
25% between gabapentin and placebo groups.   810 
 811 
G2  Interim Monitoring and Early Stopping 812 
There will not be a planned interim monitoring, nor will there be early stopping rules. 813 
G3 Statistical Methods  814 
An intention-to-treat analysis w ill be used for the primary ana lysis of the data. All 815 
participants will be examined i n the groups to which they were initially assigned. 816 
Standard descriptive statistics  will be used to assess the demo graphics, clinical 817 
characteristics, and olfactor y test results of the study popula tion. The difference in rate of 818 
responders after Fixed-Dose period will estimate the effect siz e of the primary outcome 819 
measure, and the 95% CI around that  point estimate will measure  precision. In each 820 
group, the frequency and relative frequency of the participants ’ response to the global 821 
rating of smell change will be rep orted for each Likert categor y. Fisher’s exact test will 822 
be used for comparing the responde rs’ rates between the 2 group s. Histograms and 823 
   
   
_______________________________________________________________ _______________________ 
 22Shapiro-Wilks test will be use d to test the normal distribution  assumption of the 824 
continuously measured UPSIT scores and the differences pre-post  treatment in each of 825 
the groups. Independent samples t -test or its nonparametric equ ivalent Mann-Whitney U 826 
test will be used to compare the  change in UPSIT scores between  the two groups. Mixed 827 
effects model will be used to tes t whether the change in UPSIT score from baseline to 828 
end of treatment is significantl y different bet ween 2 groups. S ubjects will be treated as 829 
random factors, and group and time will be used as fixed factor s in the model. Interaction 830 
of group by time will be explored.  Effect sizes with 95% CIs w ill be reported for each 831 
analysis. All statistical ana lyses will be conducted in SPSS 28  (IBM Corp., Armonk, 832 
NY). 833 
 834 
G4  Missing Outcome Data 835 
All attempts will be made usi ng Good Clinical Practice and thro ugh the reduction of the 836 
complexity and number of assessments to minimize the occurrence  of missing outcome 837 
data. It will be assumed that  all missing data will be at rando m. As this is a small pilot 838 
study, no computational techniques will be employed to adjust a nalyses for missing data. 839 
G5 Unblinding Procedures  840 
The blind will be broken for indi vidual participan ts for safety  concerns. Knowledge of 841 
the treatment received is necessa ry for interpreting the event,  may be essential for the 842 
medical management of the subject, and may provide critical saf ety information about 843 
gabapentin that could have imp lications for the ongoing conduct  of the trial (e.g., 844 
monitoring, informed consent).  F or unblinding, the research co ordinator will contact the 845 
research pharmacist and provide t he study ID number for the par ticipant to be unblinded.  846 
The research pharmacist will contact the PI directly and reveal  the intervention 847 
assignment.  The research coordinator will remain blinded. 848 
 849 
H Data Handling and Record Keeping  850 
 851 
H1 Confidentiality and Security 852 
Procedures that are in place t o curb risks of breaches in confi dentiality and privacy are 1) 853 
formal training protocols cente red on the maintenance of confid entiality for all study 854 
team members and  secure storage f or identified da ta such as co mpleted questionnaires 855 
and UPSIT exams; and communication with study team via secure e mail, phone line, or 856 
televideo call. 857 
 858 
Only members of the study team wi ll have access to the electron ic research files. All 859 
research data files will be st ored on secure Washington Univers ity servers with computer, 860 
network, and database-level passw ords that will only be accessi ble to study team 861 
members. Accordingly, these mechanisms intend to limit access t o information that can 862 
link clinical data to individual  participants. No participant i dentifying information will be 863 
revealed in any publicati ons or presentations. 864 
 865 
   
   
_______________________________________________________________ _______________________ 
 23Case report forms will be creat ed as electronic documents and s tored within each study 866 
participants electronic file. O riginal hard-copy source documen ts will be electronically 867 
scanned and stored in the partic ipants electronic file and stor ed in a locked file cabinet. 868 
H2 Records Retention 869 
All records will be retained for  a minimum of six years after c ompletion of the study and 870 
closure with the WU IRB. 871 
I Study Administration 872 
 873 
I1 Subject Stipends or Payments  874 
Participants will be provided a  Forte/Advarra debit card. They will receive $60 for 875 
completing all study requirement s. If participants do not compl ete all requirements, they 876 
will be paid proportionally for t he work they have completed. 877 
 878 
I2  Study Timetable 879 
 880 
January 2022: IRB approval proc ess and acquisition of resources  881 
February 2022 - March 2022: Rolling recruitment 882 
February 2022 - August 2022: 18- week clinical trial 883 
September 2022: Statistical ana lysis and publication of results  884 
 885 
J Publication Plan  886 
 887 
We plan to analyze accumulate d data throughout the month of Sep tember 2022 and 888 
publish the results by the end of  September 2022. This data inc ludes the analysis of the 889 
CGI-I, UPSIT, ODOR, NASAL-7, and C GI-P as well as a discussion of the potential 890 
adverse effects associated wit h oral gabapentin therapy for tre atment of post-COVID-19 891 
olfactory dysfunction.  892 
 893 
K  Attachments  894 
K1 Questionnaires or surveys 895 
- Screening Survey  896 
- Screening UPSIT 897 
- Week0BaselineSurvey 898 
- Blind Assessment 899 
- FixedDoseSurvey 900 
- FinalSurvey 901 
 902 
 903 
   
   
_______________________________________________________________ _______________________ 
 24L References 904 
 905 
 906 
1. Prevention CfDCa. COVID Data Tracker. https://covid.cdc.gov/covid-data- 907 
tracker/#datatracker-home . Published 2021. Accessed. 908 
2. Organization WH. WHO Cor onavirus (COVID-19) Dashboard. 909 
https://covid19.who.int/ . Published 2021. Accessed. 910 
3. Lechien JR, Chiesa-Estomba CM, De Siati DR, et al. Olfactory  and gustatory 911 
dysfunctions as a clinical presen tation of mild-to-moderate for ms of the 912 
coronavirus disease (COVID-19) : a multicenter European study. Eur Arch 913 
Otorhinolaryngol. 2020. 914 
4. Boscolo-Rizzo P, Borsetto D, F abbris C, et al. Evolution of Altered Sense of 915 
Smell or Taste in Patients W ith Mildly Symptomatic COVID-19. JAMA 916 
Otolaryngol Head Neck Surg. 2020. 917 
5. Hummel T, Rissom K, Reden J, Hahner A, Weidenbecher M, Hutte nbrink KB. 918 
Effects of olfactory training i n patients with olfactory loss. Laryngoscope. 919 
2009;119(3):496-499. 920 
6. Turner JH. Olfactory trainin g: what is the evidence? Int Forum Allergy Rhinol. 921 
2020;10(11):1199-1200. 922 
7. Biole C, Bianco M, Nunez-Gil IJ, et al. Gender Differences i n the Presentation 923 
and Outcomes of Hospitalize d Patients With COVID-19. J Hosp Med. 924 
2021;16(6):349-352. 925 
8. Butowt R, von Bartheld CS. Anosmia in COVID-19: Underlying M echanisms and 926 
Assessment of an Olfactory R oute to Brain Infection. Neuroscientist. 927 
2020:1073858420956905. 928 
9. Bilinska K, Butowt R. Anosmia in COVID-19: A Bumpy Road to E stablishing a 929 
Cellular Mechanism. ACS Chem Neurosci. 2020;11(15):2152-2155. 930 
10. Kuba K, Imai Y, Penninger JM. Multiple functions of angiote nsin-converting 931 
enzyme 2 and its relevance i n cardiovascular diseases. Circ J. 2013;77(2):301- 932 
308. 933 
11. Mollica V, Rizzo A, Massari F . The pivotal role of TMPRSS2 in coronavirus 934 
disease 2019 and prostate cancer. Future Oncol. 2020;16(27):2029-2033. 935 
12. Damm M, Pikart LK, Reimann H , et al. Olfactory training is helpful in 936 
postinfectious olfactory loss: a randomized, controlled, multic enter study. 937 
Laryngoscope. 2014;124(4):826-831. 938 
13. Schopf CL, Ablinger C, Geisler SM, et al. Presynaptic alpha 2delta subunits are 939 
key organizers of glutamatergic synapses. Proc Natl Acad Sci U S A. 940 
2021;118(14). 941 
14. Lopez-D'alessandro E, Escovich L. Combination of alpha lipo ic acid and 942 
gabapentin, its efficacy in the  treatment of Burning Mouth Synd rome: a 943 
randomized, double-blind, placebo controlled trial. Med Oral Patol Oral Cir 944 
Bucal. 2011;16(5):e635-640. 945 
15. Doty RL, Shaman P, Dann M. Dev elopment of the University of  Pennsylvania 946 
Smell Identification Test: A sta ndardized microencapsulated tes t of olfactory 947 
function. Physiol Behav. 1984;32(3):489-502. 948 
   
   
_______________________________________________________________ _______________________ 
 2516. Doty RL. Olfactory dysfunction and its measurement in the c linic. World J 949 
Otorhinolaryngol Head Neck Surg. 2015;1(1):28-33. 950 
17. Mersfelder TL, Nichols WH. Ga bapentin: Abuse, Dependence, a nd Withdrawal. 951 
Ann Pharmacother. 2016;50(3):229-233. 952 